Study of Pridopidine for the Treatment of Participants With Huntington's Disease
Study Title
- A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease
Teva Identifier
- ACR16 C009
ClinicalTrials.gov Identifier
- NCT00724048
Study Status
- Completed
Trial Condition(s)
- Huntington Disease
Interventions
- Drug: ACR16 10 mg | Drug: ACR16 22.5 mg | Drug: ACR16 45 mg | Other: Placebo
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 30 Years and older
Trial Duration
- 10/01/2008 - 06/01/2011
Phase
- Phase 2/3
Study Type
Interventional
